Detailed information for compound 213804

Basic information

Technical information
  • TDR Targets ID: 213804
  • Name: 1-[2-[2-[6-chloro-1-(4-fluorophenyl)indol-3-y l]ethyl-methylamino]ethyl]imidazolidin-2-one
  • MW: 414.904 | Formula: C22H24ClFN4O
  • H donors: 1 H acceptors: 1 LogP: 3.78 Rotable bonds: 7
    Rule of 5 violations (Lipinski): 1
  • SMILES: CN(CCc1cn(c2c1ccc(c2)Cl)c1ccc(cc1)F)CCN1CCNC1=O
  • InChi: 1S/C22H24ClFN4O/c1-26(12-13-27-11-9-25-22(27)29)10-8-16-15-28(19-5-3-18(24)4-6-19)21-14-17(23)2-7-20(16)21/h2-7,14-15H,8-13H2,1H3,(H,25,29)
  • InChiKey: YXKQXQPNOITGIQ-UHFFFAOYSA-N  

Network

Hover on a compound node to display the structore

Synonyms

  • 1-[2-[2-[6-chloro-1-(4-fluorophenyl)indol-3-yl]ethyl-methyl-amino]ethyl]imidazolidin-2-one
  • 1-[2-[2-[6-chloro-1-(4-fluorophenyl)-3-indolyl]ethyl-methylamino]ethyl]-2-imidazolidinone
  • 1-[2-[2-[6-chloro-1-(4-fluorophenyl)indol-3-yl]ethyl-methyl-amino]ethyl]-2-imidazolidinone

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Rattus norvegicus Serotonin 2a (5-HT2a) receptor Starlite/ChEMBL References
Rattus norvegicus Alpha-1a adrenergic receptor Starlite/ChEMBL References
Rattus norvegicus Dopamine D2 receptor Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Schistosoma japonicum ko:K04136 adrenergic receptor, alpha 1b, putative Alpha-1a adrenergic receptor   466 aa 386 aa 31.6 %
Echinococcus multilocularis g protein coupled receptor Alpha-1a adrenergic receptor   466 aa 414 aa 20.3 %
Schistosoma japonicum Octopamine receptor, putative Dopamine D2 receptor   444 aa 456 aa 29.4 %
Schistosoma mansoni biogenic amine receptor Dopamine D2 receptor   444 aa 452 aa 30.1 %
Echinococcus granulosus biogenic amine 5HT receptor Alpha-1a adrenergic receptor   466 aa 418 aa 30.4 %
Schistosoma mansoni biogenic amine (dopamine) receptor Dopamine D2 receptor   444 aa 494 aa 26.3 %
Onchocerca volvulus Dopamine D2 receptor   444 aa 418 aa 23.0 %
Schistosoma japonicum ko:K04209 neuropeptide Y receptor, invertebrate, putative Serotonin 2a (5-HT2a) receptor   471 aa 405 aa 25.4 %
Schistosoma mansoni muscarinic acetylcholine (GAR) receptor Dopamine D2 receptor   444 aa 487 aa 23.8 %
Onchocerca volvulus Ubiquinol-cytochrome-c reductase complex assembly factor 1 homolog Serotonin 2a (5-HT2a) receptor   471 aa 435 aa 23.0 %
Echinococcus granulosus g protein coupled receptor Alpha-1a adrenergic receptor   466 aa 399 aa 20.8 %
Schistosoma mansoni amine GPCR Dopamine D2 receptor   444 aa 424 aa 32.1 %
Echinococcus granulosus g protein coupled receptor Alpha-1a adrenergic receptor   466 aa 414 aa 20.5 %
Schistosoma japonicum ko:K04145 dopamine receptor D2, putative Dopamine D2 receptor   444 aa 432 aa 30.8 %
Echinococcus granulosus rhodopsin orphan GPCR Alpha-1a adrenergic receptor   466 aa 418 aa 20.3 %
Onchocerca volvulus Glycoprotein hormone beta 5 homolog Dopamine D2 receptor   444 aa 476 aa 24.2 %
Loa Loa (eye worm) hypothetical protein Dopamine D2 receptor   444 aa 433 aa 21.2 %
Echinococcus multilocularis g protein coupled receptor Alpha-1a adrenergic receptor   466 aa 398 aa 21.4 %
Onchocerca volvulus RB1-inducible coiled-coil protein 1 homolog Dopamine D2 receptor   444 aa 474 aa 23.4 %
Schistosoma japonicum ko:K04135 adrenergic receptor, alpha 1a, putative Alpha-1a adrenergic receptor   466 aa 443 aa 31.2 %
Echinococcus multilocularis neuropeptide Y receptor Alpha-1a adrenergic receptor   466 aa 419 aa 19.6 %
Echinococcus multilocularis serotonin receptor Dopamine D2 receptor   444 aa 428 aa 31.3 %
Schistosoma japonicum ko:K04207 neuropeptide Y receptor Y5, putative Dopamine D2 receptor   444 aa 386 aa 19.7 %
Schistosoma japonicum FMRFamide receptor, putative Alpha-1a adrenergic receptor   466 aa 374 aa 19.5 %

Obtained from network model

Ranking Plot


Putative Targets List


Species Potential target Raw Global Species
Schistosoma mansoni tyrosinase precursor 0.1812 0.5 0.5

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 0.95 nM Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]-ketanserin binding assay in rat cortical membranes ChEMBL. 8809161
IC50 (binding) = 0.95 nM Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]-ketanserin binding assay in rat cortical membranes ChEMBL. 8809161
IC50 (binding) = 14 nM Binding affinity to the alpha-1 adrenergic receptor using a radioligand [3H]-prazosin binding assay in rat brain membranes ChEMBL. 8809161
IC50 (binding) = 14 nM Binding affinity to the alpha-1 adrenergic receptor using a radioligand [3H]-prazosin binding assay in rat brain membranes ChEMBL. 8809161
IC50 (binding) = 590 nM Binding affinity to dopamine receptor D2 using a [3H]-spiperone binding assay in rat cortical membranes ChEMBL. 8809161
IC50 (binding) = 590 nM Binding affinity to dopamine receptor D2 using a [3H]-spiperone binding assay in rat cortical membranes ChEMBL. 8809161

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.